Industry Investment Rating - The report rates the pharmaceutical industry as "Leading" as of October 31, 2025 [1] Core Insights - The report highlights that the significant price reductions from the 11th batch of centralized procurement may have limited impact on the overall performance of the sector. However, catalysts in Q4 are expected to improve investor sentiment [4] - The report indicates that the pharmaceutical sector has experienced a notable price correction, but the fundamentals remain strong, with an anticipated stabilization in investment sentiment due to upcoming catalysts such as academic conferences and favorable policies [4] Summary by Relevant Sections Market Performance - The Hang Seng Index rose by 2.2% during the week of October 22-29, 2025, while the Hang Seng Healthcare Index fell by 0.9%, ranking 12th among 12 industry indices [4][10] - Sub-sectors showed varied performance, with CXO up by 4.6% and biopharmaceuticals down by 2.3% [4][10] Institutional Holdings - As of October 28, 2025, the proportion of domestic institutional holdings in the pharmaceutical sector decreased slightly to 21.9%, while foreign holdings remained stable [36][39] - Domestic investors have increased their positions in medical device companies and "AI + healthcare" concepts, while foreign investors have focused on long-term potential innovative drug companies [39] Procurement Insights - The 11th batch of centralized procurement included 55 drug products, with a selection rate of 57%. The report notes that the impact on the overall revenue of selected companies is expected to be limited [8][9] - Companies such as Kelun Pharmaceutical and China National Pharmaceutical have multiple products selected, but the overall contribution to revenue is anticipated to be small [8][9] Valuation Overview - The report provides a valuation summary for various companies, with target prices and earnings per share estimates for FY25E and FY26E, indicating a generally positive outlook for selected companies in the innovative drug sector [3] Investment Recommendations - The report recommends focusing on innovative drugs and CXO companies, highlighting specific firms such as Sanofi and WuXi AppTec as having strong short-term catalysts and undervalued growth potential [4]

Core Viewpoint - The Hong Kong Innovative Drug ETF (159567) has shown significant growth in both share volume and fund size since its inception, indicating strong investor interest and market performance [1][2]. Group 1: Fund Performance - As of October 31, 2024, the Hong Kong Innovative Drug ETF (159567) closed with a gain of 5.46% and a trading volume of 3.327 billion yuan [1]. - The fund's share volume increased by 1968.65% from 3.95 million shares at the end of 2023 to 81.79 million shares by October 30, 2024 [1]. - The fund's size grew by 1650.00%, from 378 million yuan to 6.612 billion yuan during the same period [1]. Group 2: Liquidity - Over the last 20 trading days, the cumulative trading amount for the fund reached 23.202 billion yuan, with an average daily trading amount of 1.16 billion yuan [1]. - Year-to-date, the cumulative trading amount for the fund is 234.346 billion yuan, averaging 1.172 billion yuan per day over 200 trading days [1]. Group 3: Fund Management - The current fund manager, Ma Jun, has managed the Hong Kong Innovative Drug ETF (159567) since its inception, achieving a return of 64.72% during the management period [2]. - The fund's top holdings include companies such as BeiGene, CanSino Biologics, Innovent Biologics, and others, with significant percentages of the portfolio allocated to these stocks [2].

Core Viewpoint - The 2025 National Medical Insurance Negotiation has commenced, with significant price reductions expected, exceeding initial estimates by 40%-50% for many companies [1][6]. Group 1: Negotiation Overview - The negotiation began on October 30, 2023, and is expected to last 4-5 days, starting with basic medical insurance directory negotiations followed by commercial insurance innovative drug price discussions [2][3]. - This marks the 8th adjustment of the medical insurance directory since the establishment of the National Medical Insurance Bureau, involving a five-step process: preparation, application, expert review, negotiation, and result announcement [5]. Group 2: Participants and Dynamics - Numerous representatives from major pharmaceutical companies, including domestic and international firms like Shiyao Group, Green Leaf Pharmaceutical, and Pfizer, participated in the negotiations [9]. - The pace of negotiations appeared faster than in previous years, with representatives exiting the venue more frequently without prolonged discussions [9]. Group 3: Key Changes in Negotiation Structure - A significant change this year is the introduction of a commercial insurance innovative drug directory, aimed at integrating basic medical insurance and commercial insurance, enhancing the multi-tiered medication security system [13][14]. - There are 79 drugs that applied for both the basic medical insurance directory and the commercial insurance innovative drug directory, with a sequential negotiation process established [16]. Group 4: Future Implications - The commercial insurance innovative drug directory may serve as a transitional model for innovative drug payments, allowing drugs to first enter the commercial directory before potentially being included in the basic medical insurance directory after gathering real-world data [17].

Group 1: Market Performance - The Hang Seng Hong Kong Stock Connect Innovative Drug Selection Index rose by 2.51% as of October 31, 2025, with notable increases in individual stocks such as 9.75% for 3SBio, 7.28% for InnoCare Pharma, and 5.51% for Innovent Biologics [3] - The Hong Kong Innovative Drug Selection ETF (520690) increased by 2.75%, reaching a latest price of 0.9 yuan, with a turnover rate of 9.15% and a transaction volume of 48.62 million yuan [3] - Over the past year, the average daily trading volume of the Hong Kong Innovative Drug Selection ETF was 119 million yuan [3] Group 2: Company Developments - Innovent Biologics announced its formal application for a Hong Kong listing on October 30, aiming for a dual listing in both A-share and H-share markets, which is a significant step in its global strategy [3] - The company emphasizes that this listing will support its expansion into overseas markets and strengthen its international business foundation, marking a new phase of "local deepening + global expansion" [3] Group 3: Industry Trends - Small nucleic acid drugs are recognized as the third wave in the pharmaceutical industry, with expectations for the Chinese market to exceed 10 billion yuan by 2030 [4] - The breakthrough of GalNAc technology in 2014 has significantly activated the industry, leading to commercial profitability and advancements in various therapeutic areas [4] - Chinese companies are developing in sync with global trends, expanding from cardiovascular and hepatitis B treatments to areas like weight loss and central nervous system disorders [4] Group 4: Policy and Market Outlook - The 15th Five-Year Plan emphasizes support for innovative drugs and medical devices, focusing on major diseases such as tumors and metabolic diseases, while also promoting new technology platforms like ADCs and nucleic acid drugs [5] - The latest scale of the Hong Kong Innovative Drug Selection ETF reached 523 million yuan, a new high since its inception, with a total share count of 598 million [5] - Recent net inflows into the ETF totaled 21.09 million yuan, with a significant trend of net inflows observed over the past five trading days [5] Group 5: Index Composition - As of October 8, 2025, the top ten weighted stocks in the Hang Seng Hong Kong Stock Connect Innovative Drug Selection Index accounted for 72.15% of the index [6]

Group 1 - The core viewpoint is that small nucleic acid drugs are expected to become the third major category of drugs, following small molecules and antibody drugs, due to their advantages such as targeting traditionally non-druggable targets and long-lasting effects [1] - The breakthrough of GalNAc technology in 2014 established a successful paradigm for liver-targeted delivery, significantly activating the development of the small nucleic acid drug industry [1] - The global small nucleic acid drug industry is currently achieving commercial profitability, breakthrough in indications, advancements in extrahepatic delivery, and dual-target breakthroughs [1] Group 2 - From a commercialization perspective, drugs like Amvuttra and Leqvio show significant potential, with global leader Alnylam expected to achieve profitability this year [2] - The years 2025-2026 are critical for indication breakthroughs, with weight loss indications expected to reach proof of concept (POC) and CNS indications likely to begin exploration [2] - Technological advancements in extrahepatic delivery are emerging, with TRiM and AOC delivery methods showing promise, and Avidity's AOC drug Del-zota expected to be commercially available by 2026 [2] Group 3 - Chinese small nucleic acid drug companies are demonstrating global competitiveness, with an accelerated growth in research pipelines [3] - Companies like Bewang and Ruibo have established business development (BD) transactions with multinational corporations (MNCs), showcasing the global competitiveness of Chinese small nucleic acid drugs [3] - The focus of Chinese small nucleic acid drug pipelines is expanding from cardiovascular diseases and hepatitis B to include weight loss and CNS indications, with potential for first-in-class (FIC) and best-in-class (BIC) drugs [3]

Core Points - The 2025 National Medical Insurance Negotiation (referred to as "Guo Tan") commenced on October 30, 2023, in Beijing, with negotiations expected to last 4-5 days [2][3] - This marks the 8th adjustment of the medical insurance catalog since the establishment of the National Medical Insurance Bureau, involving five stages: preparation, application, expert review, negotiation, and announcement of results [3] - A total of 644 drugs passed the formal review for the 2025 catalog, with 534 approved for the basic medical insurance catalog and 121 for the commercial insurance innovative drug catalog [3] Group 1 - The first day of negotiations focused primarily on common drugs, including those for infections, anesthesia, and diabetes, while innovative drugs are scheduled for discussion on the second and third days [3] - Some representatives expressed that the price reductions proposed by the National Medical Insurance Bureau were significantly lower than expected, with estimates being 40%-50% below the most pessimistic forecasts [3][5] - The pace of negotiations appeared to be faster than in previous years, with representatives exiting the venue every few minutes, contrasting with the lengthy discussions seen in past negotiations [5] Group 2 - The introduction of the commercial insurance innovative drug catalog is a significant change this year, aimed at integrating basic medical insurance and commercial insurance to better meet diverse medication needs [8][9] - Negotiations for the commercial insurance innovative drug catalog are expected to take place on November 1 and 2, 2023 [9] - A total of 79 drugs applied for both the basic medical insurance and commercial insurance innovative drug catalogs, with a priority given to those that successfully pass the basic medical insurance negotiations first [9][10] Group 3 - The commercial insurance innovative drug catalog will allow for greater participation from commercial insurance companies in the decision-making process regarding drug inclusion and pricing negotiations [9] - Five high-cost CAR-T products are confirmed to be included in the final negotiation list for the commercial insurance innovative drug catalog [10] - Future payment models for innovative drugs may involve initially placing them in the commercial insurance catalog before transitioning to the basic medical insurance catalog after gathering real-world data [10]

Core Insights - The top three companies by Hong Kong Stock Connect holding ratios are China Telecom (71.15%), COSCO Shipping Energy (70.14%), and GCL-Poly Energy (70.09%) [1][2] - The companies with the largest increase in holding amounts over the last five trading days are CNOOC (+2.183 billion), SMIC (+2.136 billion), and Tencent (+1.679 billion) [1][2] - The companies with the largest decrease in holding amounts over the last five trading days are Alibaba (-1.659 billion), Tracker Fund (-1.405 billion), and CSPC Pharmaceutical (-1.324 billion) [1][3] Hong Kong Stock Connect Holding Ratios - China Telecom (00728): 9.876 billion shares, 71.15% [2] - COSCO Shipping Energy (01138): 909 million shares, 70.14% [2] - GCL-Poly Energy (01330): 283 million shares, 70.09% [2] - Other notable companies include China Shenhua (67.76%) and Tianjin Capital Environmental Protection (66.42%) [2] Recent Increases in Holdings - CNOOC (00883): +2.183 billion, +10.9063 million shares [2] - SMIC (00981): +2.136 billion, +2.6983 million shares [2] - Tencent (00700): +1.679 billion, +257.85 thousand shares [2] - Other companies with significant increases include China Mobile (+1.498 billion) and Meituan (+1.186 billion) [2] Recent Decreases in Holdings - Alibaba (09988): -1.659 billion, -964.24 thousand shares [3] - Tracker Fund (02800): -1.405 billion, -5.3224 million shares [3] - CSPC Pharmaceutical (01093): -1.324 billion, -17.72074 million shares [3] - Other companies with notable decreases include Li Auto (-894 million) and BYD Company (-370 million) [3]

Group 1 - The Hang Seng Index opened with a sharp rise and maintained high-level consolidation, increasing by 0.54% by midday [1] - The consumer sector showed signs of recovery, with a slight increase of 0.12% at midday, driven by notable gains in Meituan (up 4%) and XPeng Motors (up 3.22%) [3] - The banking sector opened high but experienced a decline, stabilizing with a 0.18% increase at midday, led by HSBC Holdings (up 1.78%) and Bank of China (up 1.13%) [3] Group 2 - The healthcare sector experienced a sharp drop after opening, followed by a rebound, but ultimately fell by 1.62% at midday, with WuXi AppTec down 4.26% and China Biologic Products down 3.41% [3] - Other healthcare stocks such as Innovent Biologics and CSPC Pharmaceutical Group also saw declines exceeding 2% [3]

Core Points - The 2025 National Medical Insurance Directory negotiations have officially commenced, highlighting the importance of pharmaceutical innovation and patient access to medications [1] - The atmosphere at the negotiations is characterized by a cautious and low-key approach from pharmaceutical representatives, with an increased emphasis on confidentiality [3][4] - A total of 535 drugs are under review, with 311 outside the directory and 224 within it, alongside 121 high-value drugs reviewed under the commercial insurance innovation drug directory [9][10] Group 1: Negotiation Atmosphere - The entry process for pharmaceutical representatives was notably quieter and more orderly compared to previous years, reflecting a more subdued approach [3][4] - Representatives from both domestic and multinational pharmaceutical companies, including notable names like 恒瑞医药 and 阿斯利康, participated in the negotiations [4][9] Group 2: Key Drug Categories - Antibacterial drugs are expected to be a significant focus in the afternoon session of the negotiations, with specific products like 万古霉素 being highlighted [9][10] - Innovative drugs, including CAR-T products and new lipid-lowering medications, are also under consideration, with 恒瑞医药 presenting multiple products for initial review [10][12] Group 3: Market Insights - The PCSK9 inhibitor 瑞卡西单抗 has gained attention for its long-acting properties, with a market size of 1.32 billion yuan in 2023, representing 7.8% of the national lipid-lowering drug market [10][11] - The long-acting 阿立哌唑微球 from 丽珠集团 is another product of interest, potentially replacing oral formulations and capturing market share if included in the insurance directory [12]

Group 1 - The core viewpoint of the news is the performance and strategy of the Quan Guo Jia Yuan mixed securities investment fund, which has shown significant returns since its inception and has adjusted its portfolio in response to market conditions [1][2] Group 2 - The Quan Guo Jia Yuan fund was established on December 5, 2023, with A and C class shares achieving net value increases of 24.38% and 23.88% over the past year, surpassing the benchmark performance of 16.47% [1] - Since its inception, the A and C class shares have risen by 37.18% and 36.19%, respectively, exceeding the benchmark of 33.83% [1] - The maximum drawdown since inception for A and C class shares was -10.10% and -10.12%, respectively, outperforming the corresponding equity mixed fund index [1] - As of the end of the third quarter, the fund's stock allocation was 78.12% of net asset value, an increase of 10.11% from the second quarter [1] - The fund's investment in Hong Kong stocks accounted for 29.14%, a slight increase of 1.06% from the previous quarter [1] - The top ten holdings of the fund include Tencent Holdings, Luxshare Precision, ST Huaton, China Mobile, CATL, Zijin Mining, Ninebot, Sichuan Chengyu Expressway, CSPC Pharmaceutical, and SMIC, collectively representing 39.11% of the fund's net asset value [1] - New entries in the top ten holdings since the second quarter include CATL, Zijin Mining, Sichuan Chengyu Expressway, CSPC Pharmaceutical, and SMIC, while previous holdings such as Yangtze Power, Hengrui Medicine, Oriental Cable, Samsung Medical, and Meituan-W have exited the top ten [1] Group 3 - The fund adopts a balanced holding strategy, focusing on high dividend and new momentum sectors while flexibly seizing convertible bond investment opportunities [2] - Adjustments in holdings are based on the predictability of operating duration, dividend yield, and the certainty of dividend realization [2] - The fund has increased its investment in sub-sectors such as non-ferrous metals, semiconductors, and new energy [2] - In the convertible bond market, the fund employs a low bond premium strategy for selection and has reduced its convertible bond allocation to increase flexibility in equity investments [2]